GB9401090D0
(en)
|
1994-01-21 |
1994-03-16 |
Glaxo Lab Sa |
Chemical compounds
|
US6143746A
(en)
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
US6046206A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
|
US6060477A
(en)
*
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
US5874440A
(en)
*
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
ATE315931T1
(de)
|
1997-06-23 |
2006-02-15 |
Cellegy Pharma Inc |
Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
|
ES2137113B1
(es)
|
1997-07-29 |
2000-09-16 |
Almirall Prodesfarma Sa |
Nuevos derivados de triazolo-piridazinas heterociclicos.
|
US5852035A
(en)
*
|
1997-12-12 |
1998-12-22 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
US5942520A
(en)
*
|
1998-01-27 |
1999-08-24 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
|
US5990117A
(en)
*
|
1998-04-15 |
1999-11-23 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
|
US6124303A
(en)
*
|
1998-09-11 |
2000-09-26 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
NO20002097L
(no)
*
|
1999-04-30 |
2001-10-26 |
Lilly Icos Llc |
Fremstillingsgjenstander
|
CA2365782A1
(fr)
|
1999-04-30 |
2000-11-09 |
William E. Pullman |
Traitement des troubles de la stimulation sexuelle feminine
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
KR100738861B1
(ko)
*
|
1999-08-03 |
2007-07-16 |
릴리 아이코스 엘엘씨 |
베타-카르볼린 약학 조성물
|
US20040152106A1
(en)
*
|
1999-10-07 |
2004-08-05 |
Robertson Harold A. |
Gene necessary for striatal function, uses thereof, and compounds for modulating same
|
JP2003510349A
(ja)
*
|
1999-10-07 |
2003-03-18 |
ノヴァ−ニューロン インコーポレーテッド |
線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物
|
WO2001027112A1
(fr)
|
1999-10-11 |
2001-04-19 |
Pfizer Limited |
Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase
|
US20040254153A1
(en)
*
|
1999-11-08 |
2004-12-16 |
Pfizer Inc |
Compounds for the treatment of female sexual dysfunction
|
IL139457A0
(en)
|
1999-11-08 |
2001-11-25 |
Pfizer |
Compounds for the treatment of female sexual dysfunction
|
US6569638B1
(en)
|
2000-03-03 |
2003-05-27 |
Cell Pathways, Inc |
Method for screening compounds for the treatment of neoplasia
|
ATE343388T1
(de)
|
2000-04-19 |
2006-11-15 |
Lilly Icos Llc |
Pde-v hemmer zur behandlung von morbus parkinson
|
US6774128B2
(en)
*
|
2000-04-19 |
2004-08-10 |
Johns Hopkins University |
Methods for prevention and treatment of gastrointestinal disorders
|
ATE333457T1
(de)
|
2000-06-23 |
2006-08-15 |
Lilly Icos Llc |
Zyklische gmp-spezifische phosphodiesteraseinhibitoren
|
EP1305313A1
(fr)
*
|
2000-08-02 |
2003-05-02 |
Lilly Icos LLC |
Derives heterocycliques fusionnes utilises comme inhibiteurs de phosphodiesterase
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
NZ524572A
(en)
*
|
2000-09-06 |
2004-08-27 |
Tanabe Seiyaku Co |
Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
CA2423308A1
(fr)
|
2000-10-02 |
2002-04-11 |
Lilly Icos Llc |
Composes chimiques
|
DE60111553T2
(de)
*
|
2000-10-02 |
2006-04-06 |
Lilly Icos Llc, Wilmington |
Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
|
EP1332144B1
(fr)
*
|
2000-11-06 |
2006-08-23 |
Lilly Icos LLC |
Derives d'indole utilises comme inhibiteurs de pde5
|
AU2001296699A1
(en)
*
|
2000-11-08 |
2002-05-21 |
Lilly Icos Llc |
Condensed pyrazindione derivatives as pde inhibitors
|
US7927623B2
(en)
*
|
2001-02-15 |
2011-04-19 |
Mitsubishi Tanabe Pharma Corporation |
Tablets quickly disintegrated in oral cavity
|
DE10118305A1
(de)
*
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Zusammensetzungen zur nasalen Applikation
|
DE10118306A1
(de)
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
|
EP1401449B1
(fr)
*
|
2001-06-05 |
2007-04-25 |
Lilly Icos LLC |
Composes tetracycliques utilises comme inhibiteurs de pde5-
|
DE60213798T2
(de)
*
|
2001-06-21 |
2007-08-16 |
Lilly Icos Llc, Wilmington |
Carbolinderivate als pdev inhibitoren
|
EP1442042A1
(fr)
*
|
2001-11-09 |
2004-08-04 |
Schering Corporation |
Inhibiteurs de la phosphodiesterase v de derives polycycliques de guanine
|
IL162602A0
(en)
|
2001-12-20 |
2005-11-20 |
Applied Research Systems |
Pyrrolidine derivatives as prostaglandin modulators
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
CN100430395C
(zh)
*
|
2002-07-31 |
2008-11-05 |
利利艾科斯有限公司 |
改进的皮克特-施彭格勒反应和由该反应制备得到的产物
|
US20070010450A1
(en)
*
|
2003-06-13 |
2007-01-11 |
Microbia, Inc., A Massachusetts Corporation |
Methods and compositions for the treatment of gastrointestinal disorders
|
WO2006049986A1
(fr)
*
|
2004-10-28 |
2006-05-11 |
Dr. Reddy's Laboratories Ltd. |
Formes polymorphiques du tadalafil
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
EP2258359A3
(fr)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
|
EP1928437A2
(fr)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenese par modulation du recepteur muscarinique
|
CA2625153A1
(fr)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation de la neurogenese par inhibition de la pde
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
BRPI0618643A2
(pt)
|
2005-11-09 |
2011-09-06 |
Combinatorx Inc |
composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007134077A2
(fr)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenèse induite par le récepteur 5ht
|
EP2382975A3
(fr)
|
2006-05-09 |
2012-02-29 |
Braincells, Inc. |
Neurogénèse par modulation d'angiotensine
|
MX2009002496A
(es)
*
|
2006-09-08 |
2009-07-10 |
Braincells Inc |
Combinaciones que contienen un derivado de 4-acilaminopiridina.
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
EP2804603A1
(fr)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
|
WO2014055801A1
(fr)
|
2012-10-05 |
2014-04-10 |
Henkin Robert I |
Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
|
CN104230960B
(zh)
*
|
2013-06-06 |
2017-02-15 |
山东轩竹医药科技有限公司 |
四并环类间变性淋巴瘤激酶抑制剂
|
US20160317542A1
(en)
|
2013-12-09 |
2016-11-03 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
CN104804016B
(zh)
*
|
2014-01-23 |
2017-06-20 |
山东轩竹医药科技有限公司 |
四并环类间变性淋巴瘤激酶抑制剂
|
US10598672B2
(en)
|
2014-02-18 |
2020-03-24 |
Cyrano Therapeutics, Inc. |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
US10300042B2
(en)
|
2014-06-23 |
2019-05-28 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
CN111433210A
(zh)
|
2017-12-20 |
2020-07-17 |
诺华股份有限公司 |
作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
|
EA202091846A1
(ru)
|
2018-02-28 |
2021-06-01 |
Ферро Терапьютикс, Инк. |
Соединения с активностью, индуцирующей ферроптоз, и способы их применения
|
US11040964B2
(en)
|
2019-02-27 |
2021-06-22 |
Ferro Therapeutics, Inc. |
Compounds and methods of use
|